Menu Search
Equities

Revvity Inc

RVTY:NYQ

Revvity Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)110.98
  • Today's Change-0.13 / -0.12%
  • Shares traded242.18k
  • 1 Year change+24.03%
  • Beta1.0294
Data delayed at least 15 minutes, as of Nov 22 2024 16:20 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy5
Outperform7
Hold8
Sell1
Strong Sell0

Share price forecast in USD

The 18 analysts offering 12 month price targets for Revvity Inc have a median target of 139.00, with a high estimate of 185.00 and a low estimate of 105.00. The median estimate represents a 25.10% increase from the last price of 111.11.
High66.5%185.00
Med25.1%139.00
Low-5.5%105.00

Dividends in USD

In 2023, Revvity Inc reported a dividend of 0.28 USD, equaling last years dividend. The 10 analysts covering the company expect dividends of 0.28 USD for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in USD

On Nov 04, 2024, Revvity Inc reported 3rd quarter 2024 earnings of 1.28 per share. This result exceeded the 1.13 consensus of the 18 analysts covering the company and exceeded last year's 3rd quarter results by 8.47%.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate+3.44%
Revvity Inc reported annual 2023 earnings of 4.65 per share on Feb 01, 2024.
Average growth rate+16.94%
More ▼

Revenue history & estimates in USD

PerkinElmer, Inc. had 3rd quarter 2024 revenues of 684.05m. This bettered the 679.65m consensus of the 17 analysts covering the company. This was 1.33% above the prior year's 3rd quarter results.
Average growth rate+0.62%
PerkinElmer, Inc. had revenues for the full year 2023 of 2.75bn. This was 40.35% below the prior year's results.
Average growth rate+3.94%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.